https://doi.org/10.4081/tmr.8156
Chikungunya virus: Update on molecular biology, epidemiology and current strategies
Accepted: 28 March 2019
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Chikungunya virus (CHIKV), an arthropod-borne virus, is the aetiological agent of a disease characterized by several aspecific symptoms including fever, myalgia and arthralgia. The virus is primarily transmitted to humans through the bite of an infected mosquito of Aedes genus. This virus was first isolated in Tanzania in 1953, from which it spread to other African countries, Asia, Northern and Southern America, Europe and Oceania. Today, many human cases of CHIKV infection have been identified. The diffusion of CHIKV across the world, including Italy, is due to multiple factors amongst which the wide distribution of its vectors and high transmission efficiency play a crucial role. Currently, there are no specific treatments and effective vaccines against CHIKV; indeed, available therapies allow symptoms mitigation and some promising vaccines are undergoing clinical trials. The purpose of this review is to offer an updated picture of CHIKV molecular biology, epidemiology and vector distribution, clinical features and strategies for infection prevention and treatment.
Supporting Agencies
VALEREplus programHow to Cite
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.